260 related articles for article (PubMed ID: 26615950)
1. Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex®) through basal iridectomy (Ando) in a pseudophakic patient.
Stepanov A; Codenotti M; Ramoni A; Prati M; Jiraskova N; Rozsival P; Bandello F
Eur J Ophthalmol; 2016 Apr; 26(3):e52-4. PubMed ID: 26615950
[TBL] [Abstract][Full Text] [Related]
2. [Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases].
Malclès A; Janin-Manificat H; Yhuel Y; Russo A; Agard E; El Chehab H; Ract Madoux G; Masse H; Burillon C; Dot C
J Fr Ophtalmol; 2013 Apr; 36(4):362-7. PubMed ID: 23318000
[TBL] [Abstract][Full Text] [Related]
3. The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®).
Kang H; Lee MW; Byeon SH; Koh HJ; Lee SC; Kim M
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1819-1825. PubMed ID: 28601910
[TBL] [Abstract][Full Text] [Related]
4. Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report.
Pacella F; Agostinelli E; Carlesimo SC; Nebbioso M; Secondi R; Forastiere M; Pacella E
J Med Case Rep; 2016 Oct; 10(1):282. PubMed ID: 27733187
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.
Khurana RN; Appa SN; McCannel CA; Elman MJ; Wittenberg SE; Parks DJ; Ahmad S; Yeh S
Ophthalmology; 2014 Jan; 121(1):67-71. PubMed ID: 23890421
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal implant migration into anterior chamber in a post-vitrectomy eye with central retinal vein occlusion and persistent macular edema.
Turaka K; Kwong HM; De Souza S
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):196-7. PubMed ID: 23402344
[TBL] [Abstract][Full Text] [Related]
7. [Anterior chamber migration of a dexamethasone implant in a pseudophakic patient with a scleral-fixated posterior chamber intraocular lens].
Laplace O; Rodallec T; Akesbi J; Sandali O
J Fr Ophtalmol; 2013 Apr; 36(4):e59-61. PubMed ID: 23433821
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration.
Röck D; Bartz-Schmidt KU; Röck T
BMC Ophthalmol; 2019 May; 19(1):120. PubMed ID: 31138164
[TBL] [Abstract][Full Text] [Related]
9. Surgical Management of Anterior Chamber Migration of a Dexamethasone Intravitreal Implant.
Stelton CR; Townsend J; Peterson LT; Khurana RN; Yeh S
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(7):756-9. PubMed ID: 26247457
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone intravitreal implant (OZURDEX
Massa H; Georgoudis P; Panos GD
Ther Deliv; 2019 Jun; 10(6):343-351. PubMed ID: 31184554
[TBL] [Abstract][Full Text] [Related]
11. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].
Schmitz K; Maier M; Clemens CR; Höhn F; Wachtlin J; Lehmann F; Bertelmann T; Rüdiger K; Horn M; Bezatis A; Spital G; Meyer CH;
Ophthalmologe; 2014 Jan; 111(1):44-52. PubMed ID: 23559321
[TBL] [Abstract][Full Text] [Related]
12. Inadvertent dexamethasone implant injection into the lens body management.
Berarducci A; Sian IS; Ling R
Eur J Ophthalmol; 2014; 24(4):620-2. PubMed ID: 24519508
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes.
Khurana RN; Palmer JD; Porco TC; Wieland MR
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):56-61. PubMed ID: 25559510
[TBL] [Abstract][Full Text] [Related]
14. Anterior Chamber Migration of Ozurdex Implants.
Kayıkcıoğlu Ö; Doğruya S; Sarıgül C; Mayalı H; Kurt E
Turk J Ophthalmol; 2020 Apr; 50(2):115-122. PubMed ID: 32367704
[TBL] [Abstract][Full Text] [Related]
15. OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis: A Case-Based Discussion.
Retina; 2019 Jun; 39 Suppl 1():S1-S28. PubMed ID: 31206423
[No Abstract] [Full Text] [Related]
16. Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex).
Ong J; Davidoss NH; Bhosale A; Balaratnasingam C
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148568
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of intravitreal dexamethasone implants in macular edema excluding venous occlusions: results for a cohort of 80 patients].
Degoumois A; Akesbi J; Laurens C; Rodallec FT; Adam R; Blumen-Ohana E; Laplace O; Virevialle C; Le Dû B; Guyader V; Nordmann JP
J Fr Ophtalmol; 2015 Feb; 38(2):126-33. PubMed ID: 25592383
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome.
Mayer WJ; Kurz S; Wolf A; Kook D; Kreutzer T; Kampik A; Priglinger S; Haritoglou C
J Cataract Refract Surg; 2015 Sep; 41(9):1954-61. PubMed ID: 26603404
[TBL] [Abstract][Full Text] [Related]
19. Corneal toxicity after Ozurdex(®) migration into anterior chamber.
Bernal L; Estévez B
Arch Soc Esp Oftalmol; 2016 Jun; 91(6):292-4. PubMed ID: 26922138
[TBL] [Abstract][Full Text] [Related]
20. Dislocation of dexamethasone intravitreous implant.
Voykov B; Bartz-Schmidt KU
Arch Ophthalmol; 2012 Jun; 130(6):706. PubMed ID: 22801827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
